MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BELLEAU, B.
Right arrow Articles by TANI, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BELLEAU, B.
Right arrow Articles by TANI, H.

Molecular Pharmacology, Vol 2, 411-422, Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics

A Novel Irreversible Inhibitor of Acetylcholinesterase Specifically Directed at the Anionic Binding Site: Structure—Activity Relationships

B. BELLEAU 1 and H. TANI 1

1 Department of Chemistry, University of Ottawa, Ottawa, Ontario

Among a series of N,N-dimethyl-2-chloro-2-phenethylamines, tile prototype molecule carrying an unsubstituted phenyl ring has the unique property of irreversibly inactivating erythrocyte acetylcholinesterase when acetylcholine is the substrate. The active species responsible for this irreversible inhibition is the corresponding N,N-dimethyl-2-phenylaziridinium ion (DPA) which is generated spontaneously and quantitatively from the 2-chloroamine progenitor at neutral pH. The quaternary ion nature of DPA would allow for reversible addition complex formation with the anionic site of the enzyme and would precede slow alkylation of a nucleophile at that level. A significant stereoselectivity of the enzyme for the levo-isomer of DPA was demonstrated. Such optical selectivity is characteristic of the active surfaces of enzymes in general and of acetylcholinesterase in particular. When the phenyl ring carries substituents such as a 3'-hydroxy, 3'-methoxy, 3'-bromo, 4'-bromo, 4'-methoxy, or 3',4'-dibromo, only a reversible addition complex forms. The inability of these substituted analogs of DPA to alkylate the enzyme bears no relationship to the chemical reactivity of the aziridinium rings, but suggests rather that only the unsubstituted phenyl (as in DPA) can induce in the anionic compartment the type of fit conditioning covalent bond formation. In agreement with the view that DPA interacts with the anionic site of the enzyme, the competitive inhibitor tetramethylammonium iodide was shown to be effective in retarding irreversible inactivation. Neither prolonged dialysis nor incubation with 2-pyridine-aldoxime methochloride (PAM) can reactivate the enzyme after treatment with DPA. No correlation exists between the mode of interaction of DPA and its analogs with acetylcholinesterase and their effects at the adrenergic agr-receptor level. The unique properties of DPA suggest applications in the determination of the active sequence at the anionic binding site of acetylcholinesterase.

Note:
ACKNOWLEDGMENTS The authors are grateful to the Defence Research Board, Ottawa, for the financial support of this work. Stimulating discussions with Drs. R. M. Heggie and R. McIvor were greatly appreciated. The cooperation of Mrs. Sheila Duke in the early phases of this work is gratefully acknowledged.

Submitted on April 21, 1966







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics